Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia.

Park J, Kim S, Lim H, Liu A, Hu S, Lee J, Zhuo H, Hao Q, Matthay MA, Lee JW.

Thorax. 2018 Aug 3. pii: thoraxjnl-2018-211576. doi: 10.1136/thoraxjnl-2018-211576. [Epub ahead of print]

PMID:
30076187
2.

The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia.

Gupta N, Sinha R, Krasnodembskaya A, Xu X, Nizet V, Matthay MA, Griffin JH.

Stem Cells. 2018 May;36(5):796-806. doi: 10.1002/stem.2796. Epub 2018 Feb 14.

PMID:
29396891
3.

Concise Review: Mesenchymal Stem (Stromal) Cells: Biology and Preclinical Evidence for Therapeutic Potential for Organ Dysfunction Following Trauma or Sepsis.

Matthay MA, Pati S, Lee JW.

Stem Cells. 2017 Feb;35(2):316-324. doi: 10.1002/stem.2551. Epub 2017 Jan 19. Review.

4.

Mitochondrial Transfer via Tunneling Nanotubes is an Important Mechanism by Which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the In Vitro and In Vivo Models of ARDS.

Jackson MV, Morrison TJ, Doherty DF, McAuley DF, Matthay MA, Kissenpfennig A, O'Kane CM, Krasnodembskaya AD.

Stem Cells. 2016 Aug;34(8):2210-23. doi: 10.1002/stem.2372. Epub 2016 Apr 29.

5.

Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice.

Monsel A, Zhu YG, Gennai S, Hao Q, Hu S, Rouby JJ, Rosenzwajg M, Matthay MA, Lee JW.

Am J Respir Crit Care Med. 2015 Aug 1;192(3):324-36. doi: 10.1164/rccm.201410-1765OC.

6.

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.

Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, Levitt J, Wiener-Kronish J, Bajwa EK, Leavitt A, McKenna D, Thompson BT, Matthay MA.

Lancet Respir Med. 2015 Jan;3(1):24-32. doi: 10.1016/S2213-2600(14)70291-7. Epub 2014 Dec 17.

7.

Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis.

Walter J, Ware LB, Matthay MA.

Lancet Respir Med. 2014 Dec;2(12):1016-26. doi: 10.1016/S2213-2600(14)70217-6. Epub 2014 Oct 28. Review.

8.

Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury.

Goolaerts A, Pellan-Randrianarison N, Larghero J, Vanneaux V, Uzunhan Y, Gille T, Dard N, Plan├Ęs C, Matthay MA, Clerici C.

Am J Physiol Lung Cell Mol Physiol. 2014 Jun 1;306(11):L975-85. doi: 10.1152/ajplung.00242.2013. Epub 2014 Mar 28.

9.

Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice.

Zhu YG, Feng XM, Abbott J, Fang XH, Hao Q, Monsel A, Qu JM, Matthay MA, Lee JW.

Stem Cells. 2014 Jan;32(1):116-25. doi: 10.1002/stem.1504.

10.

Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing.

Toonkel RL, Hare JM, Matthay MA, Glassberg MK.

Am J Respir Crit Care Med. 2013 Jul 15;188(2):133-40. doi: 10.1164/rccm.201207-1204PP. Review.

PMID:
23306542
11.

Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes.

Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW, Gupta N, Petrini M, Matthay MA.

Am J Physiol Lung Cell Mol Physiol. 2012 May 15;302(10):L1003-13. doi: 10.1152/ajplung.00180.2011. Epub 2012 Mar 16.

12.

Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia.

Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov V, Matthay MA.

Thorax. 2012 Jun;67(6):533-9. doi: 10.1136/thoraxjnl-2011-201176. Epub 2012 Jan 16.

13.

Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37.

Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, Matthay MA.

Stem Cells. 2010 Dec;28(12):2229-38. doi: 10.1002/stem.544.

14.

Therapeutic potential of mesenchymal stem cells for severe acute lung injury.

Matthay MA, Thompson BT, Read EJ, McKenna DH Jr, Liu KD, Calfee CS, Lee JW.

Chest. 2010 Oct;138(4):965-72. doi: 10.1378/chest.10-0518. Review.

15.

Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1.

Fang X, Neyrinck AP, Matthay MA, Lee JW.

J Biol Chem. 2010 Aug 20;285(34):26211-22. doi: 10.1074/jbc.M110.119917. Epub 2010 Jun 16.

16.

Potential application of mesenchymal stem cells in acute lung injury.

Lee JW, Gupta N, Serikov V, Matthay MA.

Expert Opin Biol Ther. 2009 Oct;9(10):1259-70. doi: 10.1517/14712590903213651. Review.

17.

Receptor for advanced glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury.

Su X, Looney MR, Gupta N, Matthay MA.

Am J Physiol Lung Cell Mol Physiol. 2009 Jul;297(1):L1-5. doi: 10.1152/ajplung.90546.2008. Epub 2009 May 1.

18.

Supplemental Content

Loading ...
Support Center